Review



aav-php.eb-cag- hlgmn vector  (SignaGen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    SignaGen aav-php.eb-cag- hlgmn vector
    a , Representative immunoblots for total LGMN and human LGMN <t>(hLGMN)</t> in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate <t>of</t> <t>AAV-injected</t> Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).
    Aav Php.Eb Cag Hlgmn Vector, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aav-php%2Eeb-cag-+hlgmn+vector/aav+php+eb+cag++hlgmn+vector/bio_rxiv__2024__01__16__575687-192-1-14
    Average 90 stars, based on 1 article reviews
    aav-php.eb-cag- hlgmn vector - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration"

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration

    Journal: bioRxiv

    doi: 10.1101/2024.01.16.575687

    a , Representative immunoblots for total LGMN and human LGMN (hLGMN) in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate of AAV-injected Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).
    Figure Legend Snippet: a , Representative immunoblots for total LGMN and human LGMN (hLGMN) in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate of AAV-injected Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).

    Techniques Used: Western Blot, Injection, Expressing, In Vitro, Activity Assay

    a , Immunofluorescence staining of sagittal brain sections 3 months post tail vein injection of AAV-PHP.eB.CAG-hLGMN (DAPI in blue, hLGMN in cyan, n=3 mice, scale bar = 1500 μm). b , Immunofluorescence staining for neuronal marker MAP2 (magenta), microglial marker IBA1 (orange) or astrocytic marker GFAP (yellow) and DAPI (blue). White arrowheads show co-localization of hLGMN with astrocytes, green arrowheads co-localization of hLGMN with microglia. (n=3 mice, scale bar = 20 μm).
    Figure Legend Snippet: a , Immunofluorescence staining of sagittal brain sections 3 months post tail vein injection of AAV-PHP.eB.CAG-hLGMN (DAPI in blue, hLGMN in cyan, n=3 mice, scale bar = 1500 μm). b , Immunofluorescence staining for neuronal marker MAP2 (magenta), microglial marker IBA1 (orange) or astrocytic marker GFAP (yellow) and DAPI (blue). White arrowheads show co-localization of hLGMN with astrocytes, green arrowheads co-localization of hLGMN with microglia. (n=3 mice, scale bar = 20 μm).

    Techniques Used: Immunofluorescence, Staining, Injection, Marker

    Related Articles

    Plasmid Preparation:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Produced:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Transfection:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Western Blot:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Injection:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Expressing:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    In Vitro:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Activity Assay:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Immunofluorescence:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Staining:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Marker:

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration
    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.



    Similar Products

    aav-php.eb-cag- hlgmn vector  (SignaGen)
    90
    SignaGen aav-php.eb-cag- hlgmn vector
    a , Representative immunoblots for total LGMN and human LGMN <t>(hLGMN)</t> in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate <t>of</t> <t>AAV-injected</t> Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).
    Aav Php.Eb Cag Hlgmn Vector, supplied by SignaGen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/aav-php%2Eeb-cag-+hlgmn+vector/aav+php+eb+cag++hlgmn+vector/bio_rxiv__2024__01__16__575687-192-1-14
    Average 90 stars, based on 1 article reviews
    aav-php.eb-cag- hlgmn vector - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a , Representative immunoblots for total LGMN and human LGMN (hLGMN) in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate of AAV-injected Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).

    Journal: bioRxiv

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration

    doi: 10.1101/2024.01.16.575687

    Figure Lengend Snippet: a , Representative immunoblots for total LGMN and human LGMN (hLGMN) in total brain homogenate (NP40) of Grn KO mice, three months p.i. and age-matched non-injected controls, GAPDH verified equal loading. LGMN expression is quantified and normalized to Grn ko (n=3 mice per condition, mean ± s.d) b , In vitro LGMN activity assay of total brain homogenate of AAV-injected Grn ko mice and age-matched non-injected controls (n=6 mice per condition, mean ± s.d). c , Representative immunoblot of TDP-43 in the RIPA soluble fraction of total brain lysates and pTDP-43 in the urea-soluble fraction, GAPDH verified equal loading. For quantification of TDP-43 processing in the RIPA fraction, the signal of indicated TDP-43 fragments was normalized to the total TDP-43 signal (n=6 mice per condition, mean ± s.d., multiple t-tests with FDR correction). pTDP-43 accumulation in the urea fraction was quantified and normalized to Grn ko (n=6 mice per condition, mean ± s.d.), d , Representative images show assessment of hind-limb clasping phenotype in hLGMN overexpressing mice and age-matched non-injected Grn ko mice (n=6 mice per condition). The clasping phenotype was quantified (n=6 mice per condition, mean ± s.e.m.). e , Longitudinal rotarod performance of Grn ko mice overexpressing hLGMN and age-matched controls (n=6 for Grn ko + hLGMN, n=6 for Grn ko control mice, mean ± s.e.m., multiple t-tests with FDR correction). f , Plasma NfL levels were measured before injection,1.5 months p.i and terminally. (n=6, mean ± s.d.).

    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Techniques: Western Blot, Injection, Expressing, In Vitro, Activity Assay

    a , Immunofluorescence staining of sagittal brain sections 3 months post tail vein injection of AAV-PHP.eB.CAG-hLGMN (DAPI in blue, hLGMN in cyan, n=3 mice, scale bar = 1500 μm). b , Immunofluorescence staining for neuronal marker MAP2 (magenta), microglial marker IBA1 (orange) or astrocytic marker GFAP (yellow) and DAPI (blue). White arrowheads show co-localization of hLGMN with astrocytes, green arrowheads co-localization of hLGMN with microglia. (n=3 mice, scale bar = 20 μm).

    Journal: bioRxiv

    Article Title: Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration

    doi: 10.1101/2024.01.16.575687

    Figure Lengend Snippet: a , Immunofluorescence staining of sagittal brain sections 3 months post tail vein injection of AAV-PHP.eB.CAG-hLGMN (DAPI in blue, hLGMN in cyan, n=3 mice, scale bar = 1500 μm). b , Immunofluorescence staining for neuronal marker MAP2 (magenta), microglial marker IBA1 (orange) or astrocytic marker GFAP (yellow) and DAPI (blue). White arrowheads show co-localization of hLGMN with astrocytes, green arrowheads co-localization of hLGMN with microglia. (n=3 mice, scale bar = 20 μm).

    Article Snippet: The AAV-PhP.eB-CAG- hLGMN vector used in this study was produced under research-grade conditions at SignaGen by triple transfection of adherent HEK293T cells.

    Techniques: Immunofluorescence, Staining, Injection, Marker